FDA acceptance of peginesatide NDA triggers $10M milestone payment to Affymax

Download PDF Copy

Editorial Checklist

Reviewed

Affymax, IncAug 10 2011

NewsGuard 100/100 Score

Affymax, Inc. (Nasdaq:AFFY) today announced that it has received a $10 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide (formerly known as Hematide™), Affymax's investigational drug for the treatment of anemia in chronic renal failure patients. The payments were triggered by the acceptance and filing of the New Drug Application for peginesatide by the FDA.

If approved, peginesatide will be the first once-monthly erythropoiesis stimulating agent (ESA) available for the treatment of anemia associated with CKD patients on dialysis in the United States.

Source:

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anemia, Cell, Chronic, Dialysis, Erythropoiesis, Erythropoietin, Hormone, Kidney Disease, Medicaid, Medicare, New Drug Application, Pharmaceuticals, Renal Failure

Comments (0)

Download PDF Copy

Suggested Reading

Tiny molecule offers hope in reducing opioid side effects

Tiny molecule offers hope in reducing opioid side effects

Key kinase involved in cell division linked to abnormal blood vessel growth in genetic disorder

Key kinase involved in cell division linked to abnormal blood vessel growth in genetic disorder

Antibiotic resistance threatens millions of lives worldwide

Antibiotic resistance threatens millions of lives worldwide

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

AI-driven oculomics assesses HbA1c for cardiovascular risk

AI-driven oculomics assesses HbA1c for cardiovascular risk

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Early pregnancy HbA1c predicts gestational diabetes, reducing the need for complex tests

Early pregnancy HbA1c predicts gestational diabetes, reducing the need for complex tests

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Combination therapy shows promising results in treating stage 3 melanoma